Analytical method validation per the FEUM (Farmacopea de los Estados Unidos Mexicanos, the Mexican Pharmacopoeia) is a requirement every Quality Control laboratory must master when products are destined for the Mexican market: without validated methods compliant with the national pharmacopoeia, the analytical results supporting batch release are not defensible before COFEPRIS. The FEUM is the legal document established by Mexico's Ley General de Salud and, with its 14th edition in electronic format, it introduces among its new contents Appendix III, dedicated precisely to analytical method validation. In this guide we cover the Mexican regulatory framework, the required parameters, the four method categories and how to align your validation strategy with ICH Q2(R2) when the laboratory serves multiple markets.
Analytical method validation per the FEUM: the regulatory framework
The Mexican system rests on three pillars that analysts and QA must keep distinct. The first is the Ley General de Salud (General Health Law), which establishes the FEUM as the legal reference document for the identity, purity and quality of medicines and other health products marketed in Mexico. The second is the pharmacopoeia itself, published by the Comisión Permanente de la Farmacopea de los Estados Unidos Mexicanos (CPFEUM): FEUM 14.0, available electronically, gathers the monographs and the Métodos Generales de Análisis (MGA), the general chapters describing the official analytical techniques. The third pillar is the set of Normas Oficiales Mexicanas: in particular, NOM-059-SSA1-2015 on good manufacturing practices requires that the analytical methods used for the control of medicines be validated or, if compendial, that their applicability be demonstrated under the laboratory's actual conditions of use.
The operational distinction is the same one we know from Europe and the US: a non-compendial method (developed in-house or transferred) must undergo full validation; a compendial method taken from the FEUM or another recognized pharmacopoeia is not re-validated from scratch — its applicability is verified instead, and the CPFEUM has also released for consultation a document dedicated to the verification (applicability) of analytical methods. Documenting correctly which of the two scenarios applies, ideally in a dedicated SOP, is the first thing a COFEPRIS inspector checks.
FEUM Appendix III: the validation parameters
FEUM 14.0 lists among its new contents Appendix III (informative) on analytical method validation, developed by the CPFEUM's Subcomité de Validación de Métodos Analíticos and taken through the public consultations required by NOM-001-SSA1-2020. The performance parameters considered are the classic ones of analytical validation:
- Specificity/selectivity: the ability to measure the analyte without interference from excipients, impurities or degradation products;
- Linearity and working range: proportionality of the response across the method's range of use;
- Accuracy: expressed as recovery and bias against the reference value;
- Precision: repeatability and intermediate precision (different days, analysts, instruments);
- Limit of detection (LOD) and limit of quantitation (LOQ): for methods intended for impurities;
- Robustness: the method's insensitivity to deliberate, bounded variations of operating parameters.
The structure is fully recognizable to anyone already working with ICH Q2 or USP <1225>: what changes is the legal reference, not the scientific logic. One formal point deserves attention, though: in a dossier intended for COFEPRIS, protocols and reports must cite the FEUM and its MGA as the primary reference, not merely invoke international guidelines.
Working across multiple pharmacopoeias and looking for practical updates on validation, OOS and regulatory news from Mexico, Europe and the US? Subscribe to The Pragmatic GMP, GuideGxP's free weekly newsletter: every week, one laboratory and quality topic explained in operational terms, ready to use at your site.
The four method categories: what to validate for each
Like USP <1225>, the FEUM approach classifies methods into four categories according to their analytical purpose, and each category drives the parameters to be demonstrated. This is the backbone of the validation protocol: picking the wrong category means validating too much (wasting resources) or too little (generating an audit finding).
| Category | Purpose of the method | Parameters typically required |
|---|---|---|
| I – Assay (content/potency) | Quantitative determination of the active ingredient in the product or API | Specificity, linearity, accuracy, precision; LOD/LOQ not required |
| II – Impurities (quantitative) | Quantitative determination of impurities and degradation products | Specificity, linearity, accuracy, precision, limit of quantitation |
| II – Impurities (limit test) | Checking that an impurity does not exceed a limit | Specificity and limit of detection |
| III – Dissolution | Product performance (release of the active ingredient) | Specificity, linearity, accuracy, precision |
| IV – Identity | Confirmation of the analyte's identity | Specificity |
For the numerical acceptance criteria (determination coefficients, recovery ranges, number of concentration levels), the operational reference is the text of Appendix III in the current version of the FEUM: since this is a recently introduced appendix, it is good practice to check the latest published revision and the outcomes of the consulta a usuarios rounds before freezing the protocol.
FEUM and ICH Q2(R2): aligning a multi-market strategy
Since 2021 COFEPRIS has been an ICH regulatory member: convergence between Mexican requirements and international guidelines is set to grow, and the adoption of ICH Q2(R2) — the revision of the historic Q2(R1), which extends validation to techniques such as NIR and multivariate methods — makes a single validation strategy valid across markets the natural choice. The most efficient approach for a laboratory releasing both for Mexico and for Europe/US is to design the protocol around the ICH Q2(R2) perimeter and to map explicitly, in a compliance matrix, where each FEUM requirement is satisfied: the same experimental evidence, with dual regulatory traceability. Three points deserve attention in the mapping: terminology (the FEUM uses its categories and nomenclature in Spanish, which must appear in documents intended for COFEPRIS), the hierarchy of sources (in Mexico the FEUM prevails over foreign pharmacopoeias, which may be used in a supplementary role under national rules) and revision management (the CPFEUM's consulta a usuarios rounds anticipate changes: monitor them just as you monitor Ph. Eur. and USP revisions).
GuideGxP recommendation
Three moves make FEUM-based validation solid and defensible in inspection. First: formalize a validation-strategy SOP defining when you validate, when you verify applicability, and which pharmacopoeia governs each product, market by market. Second: build for every method a FEUM/ICH Q2(R2) matrix linking each parameter to its reference clause and to the experimental evidence in the report — it is the document that answers the inspector's questions before they are asked. Third: monitor the CPFEUM's consulta a usuarios as part of your laboratory's regulatory intelligence, assigning impact assessment of revisions to a specific role. To structure SOPs, protocols and quality systems on audit-ready foundations, browse our catalog of ready-to-use GxP manuals and templates, built for people working every day across QC, QA and regulatory.
